A study shows that an artificial intelligence model co-developed by researchers in the UCLA Jonsson Comprehensive Cancer Center and department of Urology at UCLA can help doctors determine the extent of cancer within the prostate.
Arjan Gower, a hematologist/oncologist at the UCLA Health Jonsson Comprehensive Cancer Center, received a $950,000 grant from the National Comprehensive Cancer Network and Taiho Oncology Inc. to help launch a multi-institutional clinical trial to test zipalertinib, an investigational drug that targets specific EGFR mutations, including Exon 20 insertions, which are known to drive cancer growth and resist standard treatments.
